DocGo (NASDAQ:DCGO) First Quarter 2024 Results

Key Financial Results

• Revenue: US$192.1m (up 70% from 1Q 2023).

• Net income: US$11.2m (up from US$3.47m loss in 1Q 2023).

• Profit margin: 5.8% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue.

• EPS: US$0.11 (up from US$0.034 loss in 1Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

DocGo EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 11%.

Looking ahead, revenue is expected to decline by 21% p.a. on average during the next 3 years, while revenues in the Healthcare industry in the US are expected to grow by 6.7%.

Performance of the American Healthcare industry.

The company's shares are down 12% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 2 warning signs for DocGo you should be aware of, and 1 of them doesn't sit too well with us.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.